Trial Profile
A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions
- Sponsors Anterogen
- 23 Aug 2023 Status changed from recruiting to completed.
- 07 Jan 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2017).
- 19 May 2017 Results from this trial published in an Abeona therapeutics Media Release.